Anti-(human Respiratory Syncytial Virus Fusion Protein)(human Monoclonal Med18897 .gamma.1-chain)
Anti-(human Respiratory Syncytial Virus Fusion Protein)(human Monoclonal Med18897 .gamma.1-chain) Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-(human Respiratory Syncytial Virus Fusion Protein)(human Monoclonal Med18897 .gamma.1-chain) is under investigation in clinical trial NCT03959488 (A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(rsv) Lower Respiratory Track Infection (LRTI) in High-risk Children).
| Trade Name | Anti-(human Respiratory Syncytial Virus Fusion Protein)(human Monoclonal Med18897 .gamma.1-chain) |
| Generic | Nirsevimab |
| Nirsevimab Other Names | Immunoglobulin g1-kappa, anti-(human respiratory syncytial virus fusion glycoprotein f0 (protein f))human monoclonal antibody.gamma.1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4*01 (90.1%)) (8.8.19) (1-126) -homo sapiens ighg1*03, Immunoglobulin g1, anti-(human respiratory syncytial virus fusion protein)(human monoclonal med18897 .gamma.1-chain), disulfide with monoclonal med18897 .kappa.-chain, dimer, Nirsevimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Anti-(human Respiratory Syncytial Virus Fusion Protein)(human Monoclonal Med18897 .gamma.1-chain)
